MV Capital Management’s Cytokinetics CYTK Stock Holding History

MV Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.05K	Buy	71 +1	+1%	+$72	﹤0.01%	608
2026 Q1	$4.61K	Buy	70 +1	+1%	+$64	﹤0.01%	638
2025 Q4	$4.38K	Hold	69	–	–	﹤0.01%	623
2025 Q3	$3.79K	Buy	69 +1	+1%	+$41	﹤0.01%	634
2025 Q2	$2.25K	Buy	68 +61	+871%	+$2.12K	﹤0.01%	695
2025 Q1	$282	Sell	7 -6	-46%	-$276	﹤0.01%	885
2024 Q4	$612	Buy	+13	New	+$675	﹤0.01%	791

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MV Capital Management's CYTK Position: Q2 2026 in Review

MV Capital Management increased its Cytokinetics (CYTK) stake by 1.4% in Q2 2026, buying an estimated $72 and bringing the position to 71 shares worth $6.05K. The position accounts for ﹤0.01% of the portfolio, ranked #608.

MV Capital Management first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

MV Capital Management held 71 shares of Cytokinetics worth $6.05K as of Q2 2026.
MV Capital Management bought 1 Cytokinetics share in Q2 2026, an estimated $72.
Cytokinetics made up ﹤0.01% of MV Capital Management's portfolio in Q2 2026, its #608 holding.
MV Capital Management first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.